{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:39:39Z","timestamp":1792111179413,"version":"4.4.0"},"reference-count":62,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PHMT"],"DOI":"10.2147\/phmt.s293246","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:01:22Z","timestamp":1644850882000},"page":"27-35","source":"Crossref","is-referenced-by-count":12,"title":["Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8910","authenticated-orcid":true,"given":"Katherine","family":"Regling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael U","family":"Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":true,"given":"Robert","family":"Sidonio Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1046\/j.1365-2516.2003.00757.x","volume":"9","author":"Panicker","year":"2003","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019000658","volume":"134","author":"Van Den Berg","year":"2019","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2516.2008.01708.x","volume":"14","author":"Mannucci","year":"2008","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1046\/j.1537-2995.1999.39111160.x","volume":"39","author":"Tabor","year":"1999","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","volume":"8","author":"Bj\u00f6rkman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/hae.12550","volume":"21","author":"Morfini","year":"2015","journal-title":"Haemophilia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1111\/jth.15395","volume":"19","author":"Versloot","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/hae.14078","volume":"26","author":"Turecek","year":"2020","journal-title":"Haemophilia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2516.2010.02318.x","volume":"16","author":"Blanchette","year":"2010","journal-title":"Haemophilia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd.2018.70","volume":"17","author":"Peters","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40265-015-0451-5","volume":"75","author":"Ragni","year":"2015","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/jth.14153","volume":"16","author":"Ragni","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/BLOOD.2019001292","volume":"135","author":"Chhabra","year":"2020","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/nejmoa2002699","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"key":"ref25","unstructured":"World Federation of Hemophilia. Online registry of clotting factor concentrates. World Federation of Hemophilia website; 2018."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"ref27","unstructured":"U.S. Food & Drug Administration. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors; 2018."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rth2.12454","volume":"5","author":"Jimenez-Yuste","year":"2021","journal-title":"Res Pr Thromb Haemost"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2019-127270","volume":"134","author":"Lucas","year":"2019","journal-title":"Blood"},{"key":"ref34","unstructured":"ATHN 7: hemophilia natural history study; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619863. Accessed September 21, 2021."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1160\/TH09-10-0732","volume":"103","author":"Bolliger","year":"2010","journal-title":"Thromb Haemost"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood.v128.22.1397.1397","volume":"128","author":"Pasi","year":"2016","journal-title":"Blood"},{"key":"ref39","unstructured":"Alnylam suspends fitusiran dosing due to thrombotic event in Phase 2 open-label extension study. World Federation of Hemophilia; 2017. Available from: https:\/\/news.wfh.org\/alnylam-suspends-fitusiran-dosing-due-thrombotic-event-phase-2-open-label-extension-study\/. Accessed December 30, 2021."},{"key":"ref40","unstructured":"Update: FDA lifts suspension of fitusiran trial. World Federation of Hemophilia; 2017. Available from: https:\/\/news.wfh.org\/update-fda-lifts-suspension-fitusiran-trial\/. Accessed December 30, 2021."},{"key":"ref41","unstructured":"Taylor NP. Sanofi plans 2021 restart for pediatric hemophilia trial hit by fallout from thrombotic events. Fierce Biotech; 2021. Available from: https:\/\/www.fiercebiotech.com\/biotech\/sanofi-plans-2021-restart-for-pediatric-hemophilia-trial-hit-by-fallout-from-thrombotic. Accessed December 30, 2021."},{"key":"ref42","first-page":"67","volume":"48","author":"Kato","year":"1996","journal-title":"Pol J Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/hae.13627","volume":"25","author":"Eichler","year":"2019","journal-title":"Haemophilia"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood.2019001542","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"ref45","unstructured":"Ray F. Novo nordisk resumes Phase 3 trials of concizumab in Hemophilia A and B. Hemophilia News Today; 2020."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/rth2.12159","volume":"3","author":"Mahlangu","year":"2019","journal-title":"Res Pr Thromb Haemost"},{"key":"ref47","unstructured":"Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy, marstacimab, for people with severe hemophilia A and B with or without inhibitors. Dow Jones Institutional News. Available from: https:\/\/cmich.idm.oclc.org\/login?url=https:\/\/www.proquest.com\/wire-feeds\/press-release-pfizer-doses-first-participant\/docview\/2463381584\/se-2?accountid=10181. Accessed December 30, 2021. 2020."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2019-122817","volume":"134","author":"Kjellev","year":"2019","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2020010331","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26865","volume":"1","author":"Nathwani","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.transci.2019.08.012","volume":"58","author":"Gollomp","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"ref53","unstructured":"Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04418414."},{"key":"ref54","unstructured":"Gene therapy trial for platelet derived factor VIII production in Hemophilia A. 2021. Available from: https:\/\/www.fiercebiotech.com\/biotech\/sanofi-plans-2021-restart-for-pediatric-hemophilia-trial-hit-by-fallout-from-thrombotic. Accessed December 30, 2021."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1182\/blood-2019-127050","volume":"134","author":"Carmona","year":"2019","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood.2020006611","volume":"136","author":"Shapiro","year":"2020","journal-title":"Blood"},{"key":"ref57","unstructured":"Al Idrus A. FDA puts Sigilon\u2019s hemophilia cell therapy trial on hold thanks to safety concerns. Fierce Biotech; 2021."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2020-137648","volume":"136","author":"Leavitt","year":"2020","journal-title":"Blood"},{"key":"ref59","unstructured":"Study to evaluate the efficacy and safety of PF-07055480\/giroctocogene fitelparvovec gene therapy in moderately severe to severe Hemophilia A adults. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04370054&cntry=&state=&city=&dist=. Accessed September 21, 2021."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"key":"ref61","unstructured":"Study to Evaluate the Efficacy and Safety of Valoctogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323098."},{"key":"ref62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rth2.12454","volume":"5","author":"George","year":"2021","journal-title":"Res Pr Thromb Haemost"}],"container-title":["Pediatric Health, Medicine and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78269","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:01:30Z","timestamp":1644850890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/managing-severe-hemophilia-a-in-children-pharmacotherapeutic-options-peer-reviewed-fulltext-article-PHMT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":62,"URL":"https:\/\/doi.org\/10.2147\/phmt.s293246","relation":{},"ISSN":["1179-9927"],"issn-type":[{"value":"1179-9927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}